NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ANAB

AnaptysBio Inc

Jul 03 • 04:00PM ET

23.75

Dollar change -0.13
Percentage change -0.54	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX BMRN ALNY IONS SRPT EXEL BLUE INCY RGEN

| Held by: VTI IWM XBI VXF IWO IBB VTWO SCHA PTH IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.84	Insider Own	10.01%	Shs Outstand	30.39M	Perf Week	1.58%
Market Cap	697.79M	Forward P/E	-	EPS next Y	-4.96	Insider Trans	-0.91%	Shs Float	26.44M	Perf Month	0.98%
Enterprise Value	703.81M	PEG	-	EPS next Q	-1.53	Inst Own	128.18%	Short Float	34.62%	Perf Quarter	25.20%
Income	-140.62M	P/S	6.24	EPS this Y	-2.88%	Inst Trans	22.90%	Short Ratio	13.98	Perf Half Y	79.65%
Sales	111.87M	P/B	21.21	EPS next Y	5.82%	ROA	-33.97%	Short Interest	9.15M	Perf YTD	79.38%
Book/sh	1.12	P/C	2.05	EPS next 5Y	-2.22%	ROE	-343.83%	52W High	41.31 -42.51%	Perf Year	-3.49%
Cash/sh	11.57	P/FCF	-	EPS past 3/5Y	-34.42% -7.30%	ROIC	-37.20%	52W Low	12.21 94.51%	Perf 3Y	14.18%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	13.05% 62.73%	Gross Margin	97.86%	Volatility	5.67% 7.10%	Perf 5Y	4.90%
Dividend TTM	-	EV/Sales	6.29	EPS Y/Y TTM	21.00%	Oper. Margin	-89.64%	ATR (14)	1.40	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.25	Sales Y/Y TTM	387.20%	Profit Margin	-125.70%	RSI (14)	57.84	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	8.25	EPS Q/Q	21.71%	SMA20	2.30%	Beta	-0.20	Target Price	42.55
Payout	-	Debt/Eq	10.17	Sales Q/Q	286.84%	SMA50	8.94%	Rel Volume	0.32	Prev Close	23.88
Employees	136	LT Debt/Eq	10.11	Earnings	May 05 AMC	SMA200	10.24%	Avg Volume	654.83K	Price	23.75
IPO	Jan 26, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	-2.15% 81.82%	Trades		Volume	212,764	Change	-0.54%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-04-25	Upgrade	H.C. Wainwright	Neutral → Buy	$38
Feb-04-25	Initiated	Wolfe Research	Outperform	$25
Dec-11-24	Downgrade	H.C. Wainwright	Buy → Neutral	$52 → $19
Dec-02-24	Downgrade	BTIG Research	Buy → Neutral
Jul-22-24	Initiated	H.C. Wainwright	Buy	$55
Jul-19-24	Upgrade	JP Morgan	Neutral → Overweight	$29 → $69
Apr-16-24	Initiated	Leerink Partners	Outperform	$47
Apr-11-24	Initiated	Wells Fargo	Overweight	$56
Mar-12-24	Upgrade	Wedbush	Neutral → Outperform	$20 → $34
Feb-26-24	Initiated	BTIG Research	Buy	$55
Feb-21-24	Initiated	Stifel	Buy	$50
Feb-16-24	Initiated	Piper Sandler	Overweight	$80
May-22-23	Upgrade	JP Morgan	Underweight → Neutral	$31 → $30
May-18-23	Initiated	TD Cowen	Outperform
Jan-06-23	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-01-22	Upgrade	Guggenheim	Neutral → Buy	$44
Sep-19-22	Resumed	H.C. Wainwright	Buy	$35
Sep-13-22	Downgrade	Truist	Buy → Hold	$50 → $28
Sep-01-22	Initiated	Raymond James	Outperform	$35
Mar-22-22	Downgrade	Guggenheim	Buy → Neutral

Show Previous Ratings

Jun-03-25 04:05PM	Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA (GlobeNewswire) +7.59% -9.57%
May-27-25 04:15PM	Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025 (GlobeNewswire)
May-12-25 03:53PM	AnaptysBio, Inc. (ANAB): Among the Unstoppable Growth Stocks to Invest in Now (Insider Monkey)
May-05-25 05:45PM	AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:15PM	Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
07:00AM	Loading…
Apr-17-25 07:00AM	Bright Peak Therapeutics Appoints John Schmid to its Board of Directors (GlobeNewswire) +7.82%
Mar-25-25 09:21AM	AnaptysBio (ANAB) Moves 9.5% Higher: Will This Strength Last? (Zacks)
Mar-24-25 09:15AM	Anaptys Announces Stock Repurchase Plan (GlobeNewswire) +9.54%
Mar-16-25 06:05AM	Wells Fargo Predicts Up to ~440% Rally for These 2 Strong Buy Stocks (TipRanks)
Feb-27-25 06:55PM	AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:15PM	Anaptys Announces Participation in March Investor Conferences (GlobeNewswire)
04:15PM	Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-13-25 10:00AM	Truist says AnaptysBio handing of placebo raise doubt about Phase 2 RA data (TipRanks) +19.44%
09:40AM	Is AnaptysBio (ANAB) Stock Outpacing Its Medical Peers This Year? (Zacks)
05:11AM	AnaptysBio (ANAB) Surges 30.5%: Is This an Indication of Further Gains? (Zacks)
12:22PM	Loading…
Feb-12-25 12:22PM	AnaptysBio achieves highest ever results in Phase II rheumatoid arthritis trial (Clinical Trials Arena) +30.51%
09:23AM	AnaptysBio Whipsaws On Promising Results In Rheumatoid Arthritis Treatment (Investor's Business Daily)
07:30AM	Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months (GlobeNewswire)
Feb-11-25 05:30PM	Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025 (GlobeNewswire)
Feb-04-25 06:37AM	Vanda and AnaptysBio link for generalised pustular psoriasis therapy (Pharmaceutical Technology)
Feb-03-25 04:15PM	Anaptys to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire) -7.08%
07:30AM	Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist (PR Newswire)
Jan-27-25 09:40AM	Are Medical Stocks Lagging AnaptysBio (ANAB) This Year? (Zacks)
Jan-13-25 09:42AM	How AnaptysBio (ANAB) Stock Stands Out in a Strong Industry (Zacks)
Jan-12-25 03:00AM	Big Biotech Fund Loads Up on a Stock That Surged in 2024, and a Loser (Barrons.com)
Jan-07-25 09:15AM	Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-12-24 05:23AM	AnaptysBios atopic dermatitis trial of BTLA agonist misses endpoints (Clinical Trials Arena)
Dec-11-24 02:07PM	AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data (Benzinga) -32.83%
08:30AM	Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis (GlobeNewswire)
Nov-25-24 09:40AM	Are Medical Stocks Lagging AnaptysBio (ANAB) This Year? (Zacks) +8.22%
12:00PM	Loading…
Nov-08-24 12:00PM	AnaptysBio (ANAB) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:35AM	Down -32.84% in 4 Weeks, Here's Why You Should You Buy the Dip in AnaptysBio (ANAB) (Zacks)
Nov-05-24 05:30PM	AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +11.72%
04:15PM	Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
04:15PM	Anaptys Announces Participation in November and December Investor Conferences (GlobeNewswire)
Aug-29-24 09:15AM	Anaptys Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-23-24 07:26AM	Why AnaptysBio Was Such a Healthy Stock This Week (Motley Fool)
Aug-14-24 04:11PM	AnaptysBio Surges After Sanofi Takes A Stake In $100 Million Offering (Investor's Business Daily) -6.35%
10:05AM	AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering (Investor's Business Daily)
05:00AM	Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering (GlobeNewswire)
Aug-05-24 09:54PM	ANAB Stock Earnings: AnaptysBio Misses EPS, Misses Revenue for Q2 2024 (InvestorPlace)
05:55PM	AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:15PM	Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-29-24 10:00AM	AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks)
Jul-22-24 02:53PM	AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst (Benzinga) +5.96%
May-09-24 05:45PM	AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -10.75%
04:15PM	Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
04:10PM	Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) (GlobeNewswire)
04:05PM	Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties (GlobeNewswire)
May-02-24 10:01AM	AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
May-01-24 04:51AM	AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock? (Zacks) +6.90%
Apr-24-24 09:00AM	Actym Therapeutics Appoints Thomas Smart as CEO (PR Newswire)
Apr-15-24 02:19PM	BTIG Research Predicts Over 118% Rally for These 3 Stocks (InvestorPlace) -6.34%
Apr-12-24 07:00PM	Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week (Motley Fool) -8.17%
Apr-09-24 02:40PM	Why You Shouldn't Bet Against AnaptysBio (ANAB) Stock. (Zacks)
Mar-14-24 12:00PM	What Makes AnaptysBio, Inc. (ANAB) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Believe AnaptysBio, Inc. (ANAB) Could Rally 69.62%: Here's is How to Trade (Zacks)
Mar-11-24 05:30PM	AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -5.85% +11.61%
04:15PM	Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-29-24 09:15AM	Anaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual Meeting (GlobeNewswire)
Feb-28-24 10:00AM	AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Feb-22-24 04:00AM	13 Best Short Squeeze Stocks To Buy Now (Insider Monkey)
Feb-19-24 05:54AM	Strength Seen in AnaptysBio, Inc. (ANAB): Can Its 5.9% Jump Turn into More Strength? (Zacks)
Jan-31-24 09:15AM	Anaptys to Present at Guggenheim's 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-12-24 03:02PM	AnaptysBio Inc CEO Daniel Faga Sells 6,866 Shares (GuruFocus.com)
Dec-07-23 09:55AM	Does AnaptysBio, Inc. (ANAB) Have the Potential to Rally 69.36% as Wall Street Analysts Expect? (Zacks)
Nov-27-23 04:15PM	Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals (GlobeNewswire)
Nov-14-23 09:35AM	Down -24.46% in 4 Weeks, Here's Why AnaptysBio, Inc. (ANAB) Looks Ripe for a Turnaround (Zacks) +7.29%
Nov-07-23 04:15PM	Anaptys Named a BioSpace 2024 Best Places to Work Winner (GlobeNewswire) -6.17%
Nov-04-23 05:41AM	AnaptysBio Inc (ANAB) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
Nov-02-23 04:15PM	Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +8.21%
Nov-01-23 09:15AM	Anaptys Announces Participation in November Investor Conferences (GlobeNewswire)
Oct-11-23 09:15AM	Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress (GlobeNewswire)
Oct-09-23 08:27AM	UPDATE 1-AnaptysBio's skin disease drug meets main goal in late-stage study (Reuters)
08:15AM	Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25 (GlobeNewswire)
08:05AM	AnaptysBio's skin disease drug meets main goal in late-stage study (Reuters)
08:00AM	Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) (GlobeNewswire)
Sep-19-23 03:01PM	Insider Sell: Eric Loumeau Sells 6,000 Shares of AnaptysBio Inc (GuruFocus.com)
Sep-18-23 04:15PM	AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors (GlobeNewswire)
Sep-12-23 09:15AM	AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit (GlobeNewswire)
Aug-07-23 04:15PM	AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-23 01:34PM	AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer (GlobeNewswire) +15.13%
Jul-04-23 06:22AM	Shareholders in AnaptysBio (NASDAQ:ANAB) are in the red if they invested five years ago (Simply Wall St.)
May-30-23 04:15PM	AnaptysBio Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-24-23 06:01AM	Need To Know: The Consensus Just Cut Its AnaptysBio, Inc. (NASDAQ:ANAB) Estimates For 2023 (Simply Wall St.)
May-22-23 01:44AM	4 big analyst picks: Norfolk Southern stock pops on 2 upgrades (Investing.com)
May-11-23 05:35PM	AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -6.31%
04:15PM	AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update (GlobeNewswire)
May-04-23 09:55AM	Wall Street Analysts Predict a 45.12% Upside in AnaptysBio, Inc. (ANAB): Here's What You Should Know (Zacks)
May-02-23 09:15AM	AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP) (GlobeNewswire)
Apr-30-23 09:47AM	When Will AnaptysBio, Inc. (NASDAQ:ANAB) Breakeven? (Simply Wall St.)
Apr-27-23 10:02AM	Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-26-23 10:02AM	Will AnaptysBio, Inc. (ANAB) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-14-23 03:13AM	CRISPR Therapeutics AG (CRSP) Soars 16.3%: Is Further Upside Left in the Stock? (Zacks)
Apr-06-23 04:15PM	AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors (GlobeNewswire)
Apr-03-23 07:14AM	Companies Like AnaptysBio (NASDAQ:ANAB) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-27-23 06:50PM	AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone in Phase 3 RUBY trial (GlobeNewswire)
Mar-01-23 05:45PM	AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Feb-27-23 04:05PM	AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference (GlobeNewswire)

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RENTON HOLLINGS	Director	Jul 02 '25	Option Exercise	6.93	20,925	145,010	25,890	Jul 03 01:34 PM
RENTON HOLLINGS	Director	Jul 02 '25	Sale	23.57	20,925	493,191	4,965	Jul 03 01:34 PM
HOLLINGS C RENTON	Director	Jul 02 '25	Proposed Sale	23.57	20,925	493,190		Jul 02 04:13 PM
FENTON DENNIS M	Director	Jun 18 '25	Sale	23.97	3,015	72,270	4,965	Jun 20 04:07 PM
RENTON HOLLINGS	Director	Jun 18 '25	Sale	23.97	3,015	72,270	4,965	Jun 20 04:06 PM
HOLLINGS C RENTON	Director	Jun 18 '25	Proposed Sale	23.97	3,015	72,270		Jun 18 04:26 PM
DENNIS M FENTON	Director	Jun 18 '25	Proposed Sale	23.97	3,015	72,270		Jun 18 04:06 PM
Jain Rita	Director	Jun 15 '25	Option Exercise	0.00	7,330	0	11,864	Jun 17 06:33 PM
FENTON DENNIS M	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	7,980	Jun 17 06:33 PM
Marquet Magda	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	9,930	Jun 17 06:32 PM
Orwin John A	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	9,365	Jun 17 06:31 PM
RENTON HOLLINGS	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	7,980	Jun 17 06:30 PM
Schmid John P.	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	52,267	Jun 17 06:30 PM
Ware J. Anthony	Director	Jun 15 '25	Option Exercise	0.00	6,030	0	13,530	Jun 17 06:29 PM
Schmid John P.	Director	Jan 13 '25	Option Exercise	6.50	42,337	275,007	46,237	Jan 15 05:04 PM
EcoR1 Capital, LLC	Director	Dec 30 '24	Buy	12.92	65,184	842,060	7,860,180	Jan 02 06:17 PM
EcoR1 Capital, LLC	Director	Dec 31 '24	Buy	12.93	13,268	171,513	7,873,448	Jan 02 06:17 PM
EcoR1 Capital, LLC	Director	Jan 02 '25	Buy	12.95	6,646	86,070	7,880,094	Jan 02 06:17 PM
RENTON HOLLINGS	Director	Nov 29 '24	Option Exercise	6.93	10,000	69,300	11,950	Dec 03 04:35 PM
RENTON HOLLINGS	Director	Nov 29 '24	Sale	25.00	10,000	250,000	1,950	Dec 03 04:35 PM
HOLLINGS C RENTON	Director	Nov 29 '24	Proposed Sale	25.00	10,000	250,000		Nov 29 01:29 PM
Lizzul Paul F.	Chief Medical Officer	Sep 23 '24	Option Exercise	18.50	1,500	27,750	16,898	Sep 24 04:18 PM
Lizzul Paul F.	Chief Medical Officer	Sep 23 '24	Sale	38.67	1,500	58,005	15,398	Sep 24 04:18 PM
PAUL F LIZZUL	Officer	Sep 23 '24	Proposed Sale	38.67	1,500	58,005		Sep 23 04:16 PM
Orwin John A	Director	Sep 15 '24	Option Exercise	0.00	1,300	0	3,335	Sep 17 06:45 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Sep 16 '24	Option Exercise	14.02	5,000	70,100	13,520	Sep 17 06:44 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Sep 14 '24	Option Exercise	0.00	6,000	0	10,740	Sep 17 06:44 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Sep 16 '24	Sale	39.82	8,720	347,270	7,020	Sep 17 06:44 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Sep 17 '24	Sale	38.41	3,780	145,191	3,240	Sep 17 06:44 PM
Lizzul Paul F.	Chief Medical Officer	Sep 16 '24	Sale	38.93	2,220	86,425	15,398	Sep 17 06:42 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	Sep 16 '24	Option Exercise	20.16	10,000	201,600	14,744	Sep 17 06:41 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	Sep 16 '24	Sale	39.91	12,220	487,725	4,744	Sep 17 06:41 PM
ERIC J LOUMEAU	Officer	Sep 17 '24	Proposed Sale	38.41	3,780	145,191		Sep 17 04:02 PM
DENNIS MULROY	Officer	Sep 16 '24	Proposed Sale	40.13	10,000	401,300		Sep 16 04:33 PM
ERIC J LOUMEAU	Officer	Sep 16 '24	Proposed Sale	40.13	6,500	260,845		Sep 16 04:22 PM
Lizzul Paul F.	Chief Medical Officer	Aug 14 '24	Option Exercise	18.50	2,000	37,000	13,618	Aug 16 04:09 PM
Lizzul Paul F.	Chief Medical Officer	Aug 14 '24	Sale	40.00	2,000	80,000	11,618	Aug 16 04:09 PM
EcoR1 Capital, LLC	10% Owner	Aug 14 '24	Buy	36.50	273,972	9,999,978	7,794,996	Aug 16 12:04 PM
PAUL F LIZZUL	Officer	Aug 14 '24	Proposed Sale	40.00	2,000	80,000		Aug 14 04:34 PM
Lizzul Paul F.	Chief Medical Officer	Jul 18 '24	Option Exercise	18.50	1,500	27,750	13,118	Jul 19 08:35 PM
Lizzul Paul F.	Chief Medical Officer	Jul 18 '24	Sale	35.00	1,500	52,500	11,618	Jul 19 08:35 PM
RENTON HOLLINGS	Director	Jul 15 '24	Option Exercise	6.93	10,000	69,300	11,950	Jul 17 04:45 PM
RENTON HOLLINGS	Director	Jul 15 '24	Sale	30.64	10,000	306,422	1,950	Jul 17 04:45 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANAB

AnaptysBio Inc

Upgrade your FINVIZ experience